

AMENDMENTS TO THE CLAIMS

1.- 79. **(Cancelled)**

80. **(Currently Amended)** A method of treating a disorder of the eye comprising administering to the eye of an individual suffering from said disorder, a cell line expressing a Neublastin polypeptide, which comprises an amino acid sequence that is at least 95% homologous to the amino acid sequence of SEQ ID NO: 12, wherein the Neublastin polypeptide binds to GFR α 3 with greater specificity as compared to GFR α 1 ~~possesses neurotrophic activity~~, wherein the cell line is genetically manipulated to express the Neublastin polypeptide, and wherein the disorder of the eye is macular degeneration, retinitis pigmentosa, or glaucoma.

81. **(Previously presented)** The method of claim 80, wherein the polypeptide comprises seven conserved cysteine residues at positions 8, 35, 39, 72, 73, 101, and 103 when numbered in accordance with SEQ ID NO: 12.

82. **(Previously presented)** The method of claim 80, wherein the polypeptide comprises amino acid residues corresponding to the following motif: C at position 16, L at position 18, V at position 25, L at position 28, G at position 29, L at position 30, G at position 31, E at position 36, F at position 40, R at position 41, F at position 42, C at position 43, G at position 45, C at position 47, C at position 80, C at position 81, R at position 82, P at position 83, F at position 91, D at position 93, S at position 105, A at position 106, C at position 109 and C at position 111, when numbered in accordance with SEQ ID NO: 12.

83. **(Previously presented)** The method of claim 80, wherein the polypeptide comprises an LGLG repeat (SEQ ID NO: 65), an FRFC motif (SEQ ID NO: 66), a QxCCRP (SEQ ID NO: 67) motif, and a SAxxCGC (SEQ ID NO: 68) motif.

84-86. **(Cancelled)**

87. **(Previously presented)** The method of claim 80, wherein the Neublastin polypeptide comprises an amino acid sequence of SEQ ID NO: 9.
88. **(Previously presented)** The method of claim 80, wherein the Neublastin polypeptide comprises an amino acid sequence of SEQ ID NO: 10.
89. **(Previously presented)** The method of claim 80, wherein the Neublastin polypeptide comprises an amino acid sequence of SEQ ID NO: 11.
90. **(Previously presented)** The method of claim 80, wherein the Neublastin polypeptide comprises an amino acid sequence of SEQ ID NO: 12.
91. **(New)** The method of claim 80, wherein the disorder of the eye is macular degeneration.
92. **(New)** The method of claim 80, wherein the disorder of the eye is retinitis pigmentosa.
93. **(New)** The method of claim 80, wherein the disorder of the eye is glaucoma.